Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies
- 1 June 1989
- journal article
- research article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 16, 83-89
- https://doi.org/10.1016/0305-7372(89)90027-3
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Nephrotoxicity of continuous intravenous infusion of recombinant interleukin-2The American Journal of Medicine, 1988
- The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.The Journal of Immunology, 1986